The Role of Osteocytes in Targeted Bone Remodeling: A Mathematical Model

TL;DR

This paper introduces a new mathematical model of bone remodeling that incorporates osteocytes, sclerostin, and RANKL expression, providing insights into targeted bone remodeling mechanisms and potential therapeutic effects.

Contribution

It extends existing models by including osteocyte roles and allows exploration of recent experimental findings and novel treatment impacts on bone remodeling.

Findings

Model demonstrates osteocyte influence on remodeling dynamics

Simulations align with recent experimental data

Framework can evaluate new bone-targeting therapies

Abstract

Until recently many studies of bone remodeling at the cellular level have focused on the behavior of mature osteoblasts and osteoclasts, and their respective precursor cells, with the role of osteocytes and bone lining cells left largely unexplored. This is particularly true with respect to the mathematical modeling of bone remodeling. However, there is increasing evidence that osteocytes play important roles in the cycle of targeted bone remodeling, in serving as a significant source of RANKL to support osteoclastogenesis, and in secreting the bone formation inhibitor sclerostin. Moreover, there is also increasing interest in sclerostin, an osteocyte-secreted bone formation inhibitor, and its role in regulating local response to changes in the bone microenvironment. Here we develop a cell population model of bone remodeling that includes the role of osteocytes, sclerostin, and allows for the possibility of RANKL expression by osteocyte cell populations. This model extends and complements many of the existing mathematical models for bone remodeling but can be used to explore aspects of the process of bone remodeling that were previously beyond the scope of prior modeling work. Through numerical simulations we demonstrate that our model can be used to theoretically explore many of the most recent experimental results for bone remodeling, and can be utilized to assess the effects of novel bone-targeting agents on the bone remodeling process.